Increase/Decrease in Cash: The total change in cash for the company over the given period.
Eagle Pharmaceuticals, Inc. (EGRX) had Increase/Decrease in Cash of $-42.34M for the most recently reported fiscal year, ending 2022-12-31.
| Income Statement Financials | |
$316.61M |
|
$35.64M |
|
$94.94M |
|
$221.67M |
|
$235.65M |
|
$80.96M |
|
$-19.53M |
|
$61.43M |
|
$61.43M |
|
$35.64M |
|
$35.64M |
|
$35.64M |
|
$35.64M |
|
$80.96M |
|
$94.70M |
|
12.93M |
|
13.06M |
|
$2.76 |
|
$2.73 |
|
| Balance Sheet Financials | |
$188.75M |
|
$1.17M |
|
$217.41M |
|
$406.16M |
|
$111.09M |
|
$56.22M |
|
$61.51M |
|
$172.60M |
|
$233.56M |
|
$70.20M |
|
$233.56M |
|
13.02M |
|
| Cash Flow Statement Financials | |
$50.70M |
|
$-86.83M |
|
$-6.21M |
|
$97.66M |
|
$55.32M |
|
|
Increase/Decrease in Cash |
$-42.34M |
$16.45M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.70 |
|
-- |
|
-- |
|
0.19 |
|
0.27 |
|
70.01% |
|
25.57% |
|
25.57% |
|
29.91% |
|
19.40% |
|
11.26% |
|
$50.52M |
|
-- |
|
-- |
|
-- |
|
0.78 |
|
1.99 |
|
4.37 |
|
83.51 |
|
15.26% |
|
50.77% |
|
8.78% |
|
12.30% |
|
$17.94 |
|
$3.87 |
|
$3.88 |
|